
ヘルス、ヘルスケア
健康的な生活を促進し、すべての人が手頃な価格で質の高い医療を受けられるようにするとともに、医療業界を変革する。
AOA Dx focuses on early-stage cancer detection within the healthcare industry. It provides diagnostic solutions that use artificial intelligence and proprietary biomarker technology to identify cancer at an early stage. Its main offering includes the GlycoLocate platform, which employs a multi-omics approach to analyse tumour markers for cancer diagnostics, and the liquid biopsy test, which is used for the detection of ovarian cancer.
